Stockreport

Theratechnologies Faces Potential Supply Disruption For Its Top Selling Drug, Warns of Revenue Impact Due To Manufacturing Delays [Yahoo! Finance]

Theratechnologies Inc. - Common Shares  (THTX) 
PDF On Tuesday, Theratechnologies Inc. (NASDAQ: THTX ) warned of a potential temporary supply disruption of Egrifta SV (tesamorelin for injection) in early 2025 The FDA h [Read more]